Biotech Spotlight: Page 2


  • Cooked vegetables in black plastic containers
    Image attribution tooltip
    Permission granted by Faeth
    Image attribution tooltip
    Q&A // Biotech Spotlight

    While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer

    The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.

    By Karissa Waddick • March 9, 2023
  • A  3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology

    With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.

    By March 2, 2023
  • Faby Malik Cytokinetics
    Image attribution tooltip
    Permission granted by Dr. Faby Malik, Cytokinetics
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Cytokinetics looks to muscle into the cardiovascular market

    With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.

    By Feb. 24, 2023
  • vaccine vial
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies

    Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.

    By Feb. 17, 2023
  • Cancer antibodies
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

    The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.

    By Feb. 16, 2023
  • Jill Milne Astria Therapeutics
    Image attribution tooltip
    Permission granted by Jill Milne, Astria Therapeutics
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Astria Therapeutics’ edge in an ultra-rare disease

    With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.

    By Feb. 1, 2023
  • Hans Schambye Galecto
    Image attribution tooltip
    Permission granted by Hans Schambye
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Galecto has identified a master switch to reduce fibroid formation

    With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.

    By Jan. 11, 2023
  • Kidney
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Chinook Therapeutics nears the finish line in kidney disease

    A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

    By Jan. 10, 2023
  • Glass vials with orange caps sit on a pharmaceutical factory production line.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

    The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.

    By Jan. 9, 2023
  • Skin
    Image attribution tooltip
    Ivan Balvan via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Evommune’s unique method of drug discovery is more than skin deep

    The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.

    By Nov. 29, 2022
  • Two researchers pipette blue liquid from beaker's to test tubes.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology

    Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.

    By Karissa Waddick • Oct. 27, 2022
  • Young African American biochemist using microscope while working on scientific research in a laboratory. The view is through the glass.
    Image attribution tooltip
    skynesher via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

    CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

    By Karissa Waddick • Oct. 11, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

    As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

    By Kim Ribbink • June 30, 2022
  • schizophrenia
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Biotech spotlight: Karuna Therapeutics’ mission to rejuvenate the field of neuroscience

    An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

    By Kim Ribbink • June 16, 2022
  • Doctor examines DNA molecules on blurred background.
    Image attribution tooltip
    Natali_Mis via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

    Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

    By May 17, 2022
  • Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

    With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

    By May 9, 2022
  • Scientists examines DNA models in modern Neurological Research Laboratory.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    How OliX Pharmaceuticals is riding the RNAi wave

    While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

    By Karissa Waddick , April 25, 2022